<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; gap</title>
	<atom:link href="http://www.tapanray.in/tag/gap/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Criticality of Bridging the Skill Gap in Today’s Indian Pharma Industry</title>
		<link>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/#comments</comments>
		<pubDate>Sun, 17 Sep 2023 07:14:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PMKVY.40.]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[skilled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[workers]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10820</guid>
		<description><![CDATA[To address the shortage of adequately skilled workers in the country, in 2023, the Government of India released a new version of the national skill development initiative called Pradhan Mantri Kaushal Vikas Yojana 4.0 (PMKVY 4.0). It is touted as a &#8230; <a href="http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma To Leverage The Art of Turning Challenges Into Opportunities, Now</title>
		<link>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now</link>
		<comments>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/#comments</comments>
		<pubDate>Mon, 20 Jul 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[respelling]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[turning]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10179</guid>
		<description><![CDATA[Since, the dawn of the year 2020, the human population living in different countries, across the world are facing ‘lockdowns in different forms. Although essential, it severely restricts normal daily essential and other important activities of all. A large number &#8230; <a href="http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patients’ Trust And Pharma Remain Strange Bedfellows?</title>
		<link>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patients-trust-and-pharma-remain-strange-bedfellows</link>
		<comments>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/#comments</comments>
		<pubDate>Mon, 03 Sep 2018 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bedfellows]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[strange]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uneasy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9129</guid>
		<description><![CDATA[Like many other industries, pharmaceutical companies too often talk about improving focus on effective ‘stakeholder-relationship management’. The doctors obviously form an integral part of this process. There is nothing wrong with it. Nevertheless, serious concern of ‘conflict of interest’ between &#8230; <a href="http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Wide Gap Between Health Care Needs, And Delivery: Is The Bridge Still Too Far?</title>
		<link>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far</link>
		<comments>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/#comments</comments>
		<pubDate>Mon, 28 Dec 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[28]]></category>
		<category><![CDATA[Ayog]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[February]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[healtrh]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[wide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7353</guid>
		<description><![CDATA[“Health inequities which abound in India must be corrected through investments in a robust primary health care system,&#8221; said Professor K Srinath Reddy, chairman, Public Health Foundation of India (PHFI), not too long ago. The equity gap between health care &#8230; <a href="http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
